Barclays analyst Andrew Mok lowered the firm’s price target on Acadia Healthcare (ACHC) to $14 from $17 and keeps an Equal Weight rating on the shares. The company cut its guidance for the third time this year due to an unexpected $49M increase in legal expenses, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Video: Marvell rises after earnings, Celestial AI deal
- Acadia Healthcare price target lowered to $19 from $22 at RBC Capital
- Acadia Healthcare price target lowered to $17 from $22 at Cantor Fitzgerald
- Acadia Healthcare price target lowered to $24 from $28 at UBS
- Leerink downgrades Acadia Healthcare on ‘real risk’ of legal liabilities